CFGenome's proprietary control technology utilizes real cfDNA while current market controls are either synthetic or fragmented genomic DNA.
This control contains ~ 10% of KRAS exon 2 G13D mutated cell-free DNA and the remaining 90% wild type KRAS background cell-free DNA. Controls with different percentages of KRAS exon 2 G13D mutated cell-free DNA are also offered.
This product has not been approved by the U.S. Food and drug administration for in vitro diagnostic use. This product is for research use only.